Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Satoru Hara
Institution:
Chiba Rosai Hospital
Observed institutions:
Chiba University,
Chiba Rosai Hospital
OpenAlex ID:
A5112873482
Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Engagement Delivers an Inhibitory Signal through the Membrane-Proximal Region in the Absence of the Tyrosine Motif in the Cytoplasmic Tail
1999
·
Chiaki Nakaseko
, Shoichiro Miyatake
, et al.
·
The Journal of Experimental Medicine
·
108
PDF
In vivo overexpression of CTLA‐4 suppresses lymphoproliferative diseases and thymic negative selection
2005
·
Shigekazu Takahashi
, Hiroshi Kataoka
, et al.
·
European Journal of Immunology
·
46
Presence of natural killer‐cell clones with variable proliferative capacity in chronic active Epstein–Barr virus infection
2001
·
Hiroshi Nagata
, Tsutomu Numata
, et al.
·
Pathology International
·
22
Successful control of Epstein–Barr virus (EBV)‐infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection
2004
·
Taeko Uehara
, Chiaki Nakaseko
, et al.
·
American Journal of Hematology
·
16
PDF
Safety and efficacy of romiplostim in patients with eltrombopag‐resistant or ‐intolerant immune thrombocytopenia
2013
·
Shokichi Tsukamoto
, Chiaki Nakaseko
, et al.
·
British Journal of Haematology
·
12
PDF
Involvement of Rap-1 activation and early termination of immune synapse in CTLA-4-mediated negative signal
2009
·
Satoru Hara
, Chiaki Nakaseko
, et al.
·
Hematology
·
11
PDF
CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy
2017
·
Yusuke Isshiki
, Chikako Ohwada
, et al.
·
Japanese Journal of Clinical Oncology
·
8
Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study)
2025
·
Ryota Imanaka
, Hiroki Numata
, et al.
·
International Journal of Hematology
·
5
PDF
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
2025
·
Tatsunori Goto
, Hiroki Numata
, et al.
·
Oncology and Therapy
·
4
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
2022
·
Yuji Okamoto
, Mitsuhito Hirano
, et al.
·
npj Systems Biology and Applications
·
4
PDF
[Epstein-Barr virus-associated lymphoproliferative disorders after BNT162b2 mRNA COVID-19 vaccination].
2023
·
Akane Tanaka
, Takeharu Kawaguchi
, et al.
·
PubMed
·
3
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study
2020
·
Kaichi Nishiwaki
, Kei‐ji Sugimoto
, et al.
·
Cancer Medicine
·
2
PDF
[Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib].
2024
·
Gentaro Koyama
, Takeharu Kawaguchi
, et al.
·
PubMed
·
1
Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML
2026
·
Jiadan Sheng
, Yasunobu Nagata
, et al.
·
Cancer Medicine
PDF
Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR4.5) : First Report from N-Road, a Phase II Study in Japan
2016
·
Kaichi Nishiwaki
, Kei-Ji Sugimoto
, et al.
·
Blood
Show more works
View as search
Works count:
15
Citation count:
242
H-index:
7
I10-index:
6
Year
Topic
Type